• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Alzheimer’s therapy may help overcome opioid addiction

Bioengineer by Bioengineer
June 5, 2019
in Health
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Clinical trial results reveal that a medication used to treat Alzheimer’s disease may also be an effective therapy for individuals addicted to opioids. The findings are published in The American Journal on Addictions.

The medication, called galantamine, is thought to have a dual mechanism of action–it increases levels of a chemical messenger called acetylcholine in the brain and also binds to nicotinic receptors, which play a role in addiction to nicotine and other substances.

Participants who took galantamine had fewer urine samples that were positive for opioids compared with those who took placebo, which corroborated with self-reported abstinence in those who took galantamine. Also, participants who used opioids during follow-up took longer to do so if they were in the galantamine group.

“My colleagues and I are excited about these preliminary findings, as they could point to new strategies for helping those with opioid use disorder. We hope to pursue this in future research,” said lead author Kathleen Carroll, PhD, of the Yale University School of Medicine.

###

Media Contact
Penny Smith
[email protected]
http://dx.doi.org/10.1111/ajad.12904

Tags: AddictionDrugsMedicine/HealthPublic Health
Share13Tweet8Share2ShareShareShare2

Related Posts

TMolNet: Revolutionizing Molecular Property Prediction

September 21, 2025

NICU Families’ Stories Through Staff Perspectives

September 21, 2025

CT Scans in Kids: Cancer Risk Insights

September 20, 2025

Revealing Tendon Changes from Rotator Cuff Tears

September 20, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    156 shares
    Share 62 Tweet 39
  • Physicists Develop Visible Time Crystal for the First Time

    68 shares
    Share 27 Tweet 17
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    49 shares
    Share 20 Tweet 12
  • Scientists Achieve Ambient-Temperature Light-Induced Heterolytic Hydrogen Dissociation

    48 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Key Drivers of Corporate Governance in Burundi’s Cooperatives

Revolutionizing Sustainable Construction: The Role of Cardboard and Earth

TMolNet: Revolutionizing Molecular Property Prediction

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.